Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sage Therapeutic Com (SAGE)

83.315   -1.725 (-2.03%) 02-25 12:06
Open: 85.68 Pre. Close: 85.04
High: 86.535 Low: 82.405
Volume: 319,805 Market Cap: 4,864M
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 87.976 - 88.468 88.468 - 88.919
Low: 77.088 - 77.679 77.679 - 78.22
Close: 84.124 - 85.04 85.04 - 85.879

Technical analysis

as of: 2021-02-25 11:50:39 AM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 101.68     One year: 109.34
Support: Support1: 76.44    Support2: 63.60
Resistance: Resistance1: 87.05    Resistance2: 93.61
Pivot: 82.33
Moving Average: MA(5): 82.52     MA(20): 81.77
MA(100): 78.17     MA(250): 56.87
MACD: MACD(12,26): -0.47     Signal(9): -0.68
Stochastic oscillator: %K(14,3): 51.52     %D(3): 42.94
RSI: RSI(14): 51.32
52-week: High: 98.39  Low: 25.01  Change(%): 78.5
Average Vol(K): 3-Month: 60303  10-Days: 41594

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
SAGE has closed below upper band by 32.1%. Bollinger Bands are 40.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to SAGE's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 25 Feb 2021
HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat

Thu, 25 Feb 2021
Canaccord Genuity Stick to Their Buy Rating for SAGE Therapeutics By -

Thu, 25 Feb 2021
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), SAGE Therapeutics (SAGE) and G1 Therapeutics (GTHX) - Smarter Analyst

Wed, 24 Feb 2021
Sage Therapeutics Inc. (SAGE) Soars 5.98% on February 24 -

Wed, 24 Feb 2021
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha

Wed, 24 Feb 2021
Edited Transcript of SAGE.OQ earnings conference call or presentation 24-Feb-21 1:00pm GMT - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 58
Shares Float (M) 46
% Held by Insiders 1.60
% Held by Institutions 93.80
Shares Short (K) 5,290
Shares Short P. Month (K) 5,310

Stock Financials

EPS -10.350
EPS Est This Year -7.400
EPS Est Next Year -7.690
Book Value (p.s.) 12.640
Profit Margin
Operating Margin -7521.01
Return on Assets (ttm) -33.8
Return on Equity (ttm) -61.8
Qtrly Rev. Growth -54.1
Gross Profit (p.s.) -6.216
Sales Per Share 0.120
EBITDA (p.s.) -8.953
Qtrly Earnings Growth
Operating Cash Flow (M) -463
Levered Free Cash Flow (M) -252

Stock Valuations

PE Ratio -8.10
PEG Ratio
Price to Book value 6.64
Price to Sales 701.49
Price to Cash Flow -10.55

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.